MDT Medtronic Plc

Medtronic Recognized with Prestigious Catalyst Award

Medtronic Recognized with Prestigious Catalyst Award

DUBLIN, Jan. 16, 2020 (GLOBE NEWSWIRE) --   (NYSE:MDT), the global leader in medical technology, has been named one of three recipients of the , which recognizes corporations and the groundbreaking initiatives they’ve created to foster an inclusive workplace where women can advance.

Medtronic is being recognized for the Medtronic Women’s Network (MWN) and Women in Science and Engineering (WISE) initiatives, key drivers in the company’s overall Inclusion and Diversity strategy.

One of five internally established diversity networks within the company, the MWN was refocused by Medtronic CEO Omar Ishrak in 2013 with the idea that diverse perspectives and people produce better decisions, better outcomes and better business performance. MWN is run by employee volunteers – men and women from around the world – who are committed to creating an inclusive workplace while fulfilling the company mission of alleviating pain, restoring health, and extending life. The MWN has more than 15,000 members in 68 countries who gain leadership and functional experience to advance their careers. They are empowered to drive holistic change, and MWN strategies are directly linked to company and performance metrics, success measures and advancement opportunities.

Medtronic’s WISE program focuses on advancing women in R&D and STEM roles. The comprehensive program seeks to build an inclusive work environment for women in science and engineering through outreach, recruiting, talent development and cultural awareness programs. WISE teams are currently active in 70 Medtronic sites across the United States, Canada, China, Europe, India, Israel and Japan.

As a result of these global initiatives, from 2015 – 2019 Medtronic has seen an increase in women leaders from 32 percent to 38 percent. In addition, women VP roles increased from 24 percent to 30 percent; women at the director level increased from 30 percent to 36 percent; and women in R&D increased from 24 percent to 29 percent. Today, 40 percent of Medtronic therapy revenue is led by women.

“To us, this is more than hitting a number,” said Omar Ishrak, Medtronic chairman and chief executive officer. “This is about creating a more inclusive culture that values all dimensions of diversity – because a more diverse culture fosters a more innovative culture, and innovation fuels our company growth.”

“We are known for innovation, and we need women in the mix,” said Carol Malnati, vice president of Research and Development for the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic. “Attracting and developing women, including female engineers, is a core strategy.”

Since 1987,  has recognized nearly 100  at 89 organizations from around the world. Medtronic and this year’s other winning companies will be honored at the annual Catalyst Awards Conference and Dinner on Thursday, March 12, 2020, at the New York Hilton Midtown. Keynote speaker will be Indra Nooyi, former chairman and chief executive officer of PepsiCo. Last year’s conference drew more than 1,500 attendees.

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

 

 

Erika Winkels

Public Relations

Ryan Weispfenning

Investor Relations

EN
16/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Medtronic, plc: Key facts and statistics - LTM October 2025

A summary company profile, detailing Medtronic plc’s business operations and financial highlights.

Medtronic Plc: 1 director

A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch